STOCK WATCH

SHARES in Faron Pharmaceuticals tanked as it revealed the trial of its drug may have been affected by other medications the patients were taking.

The phase three trial of Traumakine, designed to alleviate acute respiratory distress syndrome, produced disappointing results when it concluded earlier this year.

But Faron has said the mortality rate among patients was significantly less when they took Traumakine alone, rather than with corticosteroids. Shares fell 26.3pc, or 31.5p, to 89p.